Grant: Collaborative Research and Development Grants
Institut national de la recherche scientifique
$70,000.00
Prevention of colorectal cancer development by Bio-K+ probiotic formula
EF 2013-14
Résumé
Colon cancer is one of the leading causes of morbidity and mortality, not only in Western industrialized countries but also in developed Asian countries. Currently, colorectal cancer (CRC) is the 2nd leading cause of cancer death in Canada (after lung cancer). The most recent estimated statistics for CRC for 2009 are: 22,000 new cases and 9,100 deaths. Estimated CRC deaths in Canada in 2009 are 9,100 (Canadian Cancer Society). Therefore, prevention of cancer in generally and colon cancer in specifically is very important. The use of probiotic bacteria in cancer chemoprevention is an active preventive strategy to inhibit, delay or reverse human carcinogenesis. Some studies have proposed that microbial cell wall components from probiotic bacteria (ex: bacterial peptidoglycans) could be responsible of cancer prevention. However, no study have been done to confirm this hypothesis and to elucidate their mechanisms in cancer prevention. In an in vitro anti-proliferative test against colon cancer cell line, it was found that there was a synergistic effect of Bio-K+? bacterial strains with 5-Fluorouracil in enhancing the apoptosis in a colon cancer cell line. In another research on in vivo prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogen, Bio-K+? fermented milk was demonstrated to be able to reduce significantly the formation of ACF (a precancerous lesion in rat intestine and related to colon cancer). Based on our recent research, we suppose that BioK+? fermented milk at an optimized dose will have a strong in vivo activity in prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogenic agent. It is also supposed that bioactive components produced by probiotic strains during milk fermentation to produce Bio-K+? products may be the main components in reduction of ACF formation in rats. The objectives of this work are 1) to investigate the dose-effects of BioK+? fermented milk in reducing precancerous lesions in in vivo test and 2) to fractionate bioactive compounds from BioK+? fermented milk and evaluate their effects in reducing precancerous lesions in in vivo test.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
418002-2011
Name nom
Lacroix, Monique
Department département
INRS-Institut Armand-Frappier
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
70000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
501
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Processed food products and beverages
Area of application fr
Aliments transformés et boissons
Research subject code
6102
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food microbiology
Research subject fr
Microbiologie alimentaire
Partie
2
Nb partie
2
Application title
Prevention of colorectal cancer development by Bio-K+ probiotic formula
Keyword
NSERC
Application summary
Colon cancer is one of the leading causes of morbidity and mortality, not only in Western industrialized countries but also in developed Asian countries. Currently, colorectal cancer (CRC) is the 2nd leading cause of cancer death in Canada (after lung cancer). The most recent estimated statistics for CRC for 2009 are: 22,000 new cases and 9,100 deaths. Estimated CRC deaths in Canada in 2009 are 9,100 (Canadian Cancer Society). Therefore, prevention of cancer in generally and colon cancer in specifically is very important. The use of probiotic bacteria in cancer chemoprevention is an active preventive strategy to inhibit, delay or reverse human carcinogenesis. Some studies have proposed that microbial cell wall components from probiotic bacteria (ex: bacterial peptidoglycans) could be responsible of cancer prevention. However, no study have been done to confirm this hypothesis and to elucidate their mechanisms in cancer prevention. In an in vitro anti-proliferative test against colon cancer cell line, it was found that there was a synergistic effect of Bio-K+? bacterial strains with 5-Fluorouracil in enhancing the apoptosis in a colon cancer cell line. In another research on in vivo prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogen, Bio-K+? fermented milk was demonstrated to be able to reduce significantly the formation of ACF (a precancerous lesion in rat intestine and related to colon cancer). Based on our recent research, we suppose that BioK+? fermented milk at an optimized dose will have a strong in vivo activity in prevention of aberrant crypt foci (ACF) formation in rats treated with a carcinogenic agent. It is also supposed that bioactive components produced by probiotic strains during milk fermentation to produce Bio-K+? products may be the main components in reduction of ACF formation in rats. The objectives of this work are 1) to investigate the dose-effects of BioK+? fermented milk in reducing precancerous lesions in in vivo test and 2) to fractionate bioactive compounds from BioK+? fermented milk and evaluate their effects in reducing precancerous lesions in in vivo test.